Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04295759 · ClinicalTrials.gov registry record · Phase 1
INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
A Phase 1 study, sponsored by Pediatric Brain Tumor Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT04295759: Completed Phase 1 study, sponsored by Pediatric Brain Tumor Consortium.
NCT04295759 is a Phase 1 study that has completed, run by Pediatric Brain Tumor Consortium. The registered enrollment target is 13 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04295759, a Phase 1 study, has completed, sponsored by Pediatric Brain Tumor Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a multicenter phase 1 trial of INCB7839 for children with recurrent or progressive high-grade gliomas, including, but not limited to, diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs), after upfront therapy.
Primary Outcome
All subjects evaluable for dose-finding were classified as having DLT or not having DLT, and the number of subjects having DLT was reported. Any INCB7839-related adverse events during the first course of treatment that led to dose reduction, permanent cessation of therapy, or a delay in treatment of \>7 days were considered DLTs. Hematologic DLTs included any grade 4 hematologic toxicity except lymphopenia; grade 3 neutropenia with fever; or requiring a platelet transfusion on 2 separate days du
Interventions
- DRUG INCB7839
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2020-07-27 |
| Est. Completion | 2024-12-01 |
| Phase | Phase 1 |
What the finished NCT04295759 record still lists
NCT04295759 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 1 intervention - of which INCB7839 is the first listed.
NCT04295759 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04295759 about?
NCT04295759 is a clinical study titled "INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas". This is a multicenter phase 1 trial of INCB7839 for children with recurrent or progressive high-grade gliomas, including, but not limited to, diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs), after upfront therapy.
What is the current status of trial NCT04295759?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2020-07-27. Estimated completion is 2024-12-01.
What interventions are being tested in trial NCT04295759?
The interventions under investigation include: INCB7839 (DRUG).
Who is sponsoring clinical trial NCT04295759?
This trial is sponsored by Pediatric Brain Tumor Consortium, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04295759's enrollment target sits among peer trials
13 1847th of 2000 higher than 149 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI